Azole-Induced Myositis after Combined Lung-Liver Transplantation
Lung transplant recipients experience a high rate of invasive pulmonary aspergillosis infections, for which voriconazole is the treatment of choice. We report a patient who developed voriconazole-induced myositis that relapsed after one dose of isavuconazole. Our patient was a 38-year-old man who re...
Saved in:
Main Authors: | Sofie Happaerts, Michiel Wieërs, Ward Vander Mijnsbrugge, Laurent Godinas, Dirk Van Raemdonck, Laurens J. Ceulemans, Robin Vos, Geert M. Verleden |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-01-01
|
Series: | Case Reports in Transplantation |
Online Access: | http://dx.doi.org/10.1155/2022/7323755 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Innovations in Lung Transplant Research and Practice: The Future is Now
by: Robin Vos, et al.
Published: (2025-02-01) -
Impact of the use of azole fungicides, other than as human medicines, on the development of azole‐resistant Aspergillus spp.
by: European Food Safety Authority (EFSA), et al.
Published: (2025-01-01) -
Picking interstitial lung disease out of the myositis haystack
by: Jennifer Hannah, et al.
Published: (2020-01-01) -
The evolving spectrum of interstitial lung disease in myositis—Management pearls
by: Takahisa Gono
Published: (2020-01-01) -
Monoclonal Antibodies in Prevention and Early Treatment of COVID-19 in Lung Transplant Recipients: A Systematic Review and Perspective on the Role of Monoclonal Antibodies in the Future
by: David A. Van Eijndhoven, et al.
Published: (2025-02-01)